Last reviewed · How we verify
Praluent
At a glance
| Generic name | Praluent |
|---|---|
| Also known as | Alirocumab, REGN727, SAR236553 |
| Sponsor | Regeneron Pharmaceuticals |
| Target | Proprotein convertase subtilisin/kexin type 9 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Atherosclerosis
- Complex dyslipidemia
- Familial hypercholesterolemia - heterozygous
- Hypercholesterolemia
Common side effects
- Injection site reactions (erythema/redness, itching, swelling, pain/tenderness)
- Myalgia
- Influenza
Serious adverse events
- Allergic reactions
- Elevated liver enzymes
Key clinical trials
- Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (EARLY_PHASE1)
- A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia (PHASE2)
- Cardiac Allograft Vasculopathy Inhibition With Alirocumab (PHASE2)
- TOP 2301: Neoadjuvant Chemo for NSCLC (PHASE2)
- Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
- Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction (PHASE4)
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung (PHASE2)
- Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Praluent CI brief — competitive landscape report
- Praluent updates RSS · CI watch RSS
- Regeneron Pharmaceuticals portfolio CI